Core Viewpoint - The announcement highlights the progress of China's biopharmaceutical company in the development of innovative drugs, particularly the completion of the first dosing of TQB6411, an EGFR/c-MET dual antibody ADC [1] Group 1: Drug Development Progress - The first subject has been dosed with TQB6411, an innovative drug targeting EGFR and c-MET [1] - In addition to TQB6411, the company has several other ADC projects in various clinical stages: TQB2102 (HER2 dual antibody ADC) is in Phase III, LM-302 (CLDN18.2 ADC) is also in Phase III, and LM-305 (GPRC5D ADC) is in Phase I/II [1] - TQB2101 (ROR1 ADC) is currently in Phase I, and numerous ADC projects are in preclinical development, expected to enter clinical stages in the next 1-2 years [1]